Lucintel's latest study found that, The future of the global vertigo treatment market looks promising with opportunities in the hospital pharmacy, drug store & retail pharmacy, and online provider markets. The global vertigo treatment market is expected to reach an estimated $1.6 billion by 2030 with a CAGR of 4.1% from 2024 to 2030. The major drivers for this market are growing numbers of adults and older people experiencing vertigo, an increase in the geriatric population, more knowledge of inner ear issues and their causes, and the availability of therapies for vertigo difficulties.
In this market, peripheral vertigo and central vertigo are the major segments of vertigo treatment market by type.
Lucintel forecasts that peripheral vertigo is expected to witness the higher growth over the forecast period due to rise in benign paroxysmal positional vertigo prevalence.
Browse in depth TOC of the Vertigo Treatment Market
100 - Figures
150-Pages
Vertigo Treatment Market is marked by presence of several big and small players. Epic Pharma, Pfizer, Glaxosmithkline, Endo Pharmaceuticals, Astrazeneca, Sanofi, Zydus Cadila, Hoffmann-La Roche, Sun Pharmaceutical Industries, and Teva Pharmaceutical are the major suppliers in the vertigo treatment market.
This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or click on this link [email protected]